MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.30
+0.05
+0.80%
After Hours: 6.30 0 0.00% 16:00 09/17 EDT
OPEN
6.26
PREV CLOSE
6.25
HIGH
6.48
LOW
6.20
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
21.70
52 WEEK LOW
4.200
MARKET CAP
174.96M
P/E (TTM)
-1.4811
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADMS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADMS News

  • Buy Bellus Health Before It Hits The Nasdaq
  • Seeking Alpha - Article.1d ago
  • Easy Come, Easy Go: How Adamas Pharmaceuticals (NASDAQ:ADMS) Shareholders Got Unlucky And Saw 71% Of Their Cash Evaporate
  • Simply Wall St..4d ago
  • Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer
  • GlobeNewswire.4d ago
  • New CEO at Adamas Pharma
  • Seeking Alpha - Article.4d ago

More

Industry

Biotechnology & Medical Research
-0.22%
Pharmaceuticals & Medical Research
+0.42%

Hot Stocks

Name
Price
%Change

About ADMS

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
More

Webull offers Adamas Pharmaceuticals Inc (ADMS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.